Clinical trials of diabetic neuropathy: Past, present, and future

Diabetes

Volumn 44, Issue 12, 1995, Pages 1355-1361

  Pfeifer, Michael A ^a   Schumer, Mary P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; DIABETES CONTROL; DIABETIC NEUROPATHY; FOLLOW UP; MORPHOMETRICS; NERVE FUNCTION; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

EID: 0028859525     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.44.12.1355     Document Type: Review

References (51)

1. Greene DA, Sima AAF, Pfeifer MA: Pathophysiology of diabetic neuropathy. In Diabetes Mellitus. Rifkin H, Porte D Jr, Eds. New York, Elsevier, 1990, p. 710-755
2. Pfeifer MA, Weinberg CR, Cook DL, Reenan A, Halar E, Halter JB, LaCava EC, Porte D Jr: Correlation among autonomic, sensory, and motor neural function tests in untreated non-insulin-dependent diabetic individuals. Diabetes Care 8:576-584, 1985
3. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561-568, 1995
4. Pfeifer M, Cleary P, Kenny D, Schumer M, Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on measures of autonomic nervous system (ANS) function in the diabetes control and complications trial (DCCT) (Abstract). Diabetes 44:30A, 1995
5. 2 analogue on diabetic neuropathy of rats (Abstract). Diabetes 42 (Suppl. 1):101A, 1993
6. Cameron NE, Cotter MA, Robertson S: Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 30:46-48, 1993
7. Cameron NE, Cotter MA, Robertson S: Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 35:12-18, 1993
8. Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Sima A, Greene D: The linked roles of nitric oxide, aldose reductase and (Na+, K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94:853-859, 1994
9. Sima AA, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B, Tolrestat Study Group: Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy: The Tolrestat Study Group. J Diabetic Complications 7:157-169, 1993
10. Sima AA, Nathaniel V, Prashar A, Bril V, Greene DA: Endoneurial microvessels in human diabetic neuropathy: endothelial cell dysfunction and lack of treatment effect by aldose reductase inhibitor. Diabetes 40:1090-1099, 1991
11. Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang K-Y, Gabbay KH, Rubenstein AH, Porte D Jr: Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 308:119-124, 1983
12. Santiago JV, Sönksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B, Tolrestat Study Group: Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetic Complications 7:170-178, 1993
13. Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosn I, Sönksen P, United Kingdom/Scandinavian Ponalrestat Trial Group: Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. J Diabetic Complications 6:123-130, 1992
14. Ziegler D, Mayer P, Rathmann W, Gries FA: One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 14:63-73, 1991
15. Boulton AJ, Levin S, Comstock J: A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33:431-437, 1990
16. Greene DA, Lattimer SA: Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor. Am J Med 79:13-17, 1985
17. Jaspan JB, Towle VL, Maselli R, Herold K: Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism 35 (Suppl. 1):83-92, 1986
18. Jaspan J, Maselli R, Herold K, Bartkus C: Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet ii:758-762, 1983
19. Sorbinil Retinopathy Trial Research Group: The Sorbinil Retinopathy Trial: neuropathy results. Neurology 43:1141-1149, 1993
20. Clements R: Dietary myoinositol intake and peripheral nerve function in diabetic neuropathy. Metabolism 28 (Suppl. 1):477-483, 1979
21. Greene DA, DeJesus PV Jr, Winegrad AI: Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55:1326-1336, 1975
22. Gregersen G, Brsting H, Theil P, Servo C: Myoinositol and function of peripheral nerves in human diabetics: a controlled clinical trial. Acta Neurol Scand 58:241-248, 1978
23. Salway JG, Finnegan JA, Barnett D, Whitehead L, Karunanayaka A, Payne RB: Effect of myo-inositol on peripheral nerve function in diabetes. Lancet ii: 1282-1284, 1978
24. Monckton G, Marusyk H: The effects of myoinositol on the autonomic neuropathy in the streptozotocin diabetic rat: a freeze fracture study. Can J Neurol Sci 15:147-151, 1988
25. Vlassara H, Brownlee M, Cerami A: Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation end products. J Exp Med 160:197-207, 1984
26. Vlassara H, Brownlee M, Cerami A: Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA 78:5190-5192, 1981
27. Tomlinson DR, Mayer JH: Defects of axonal transport in diabetes mellitus: a possible contribution to the aetiology of diabetic neuropathy. J Auton Pharmacol 4:59-72, 1984
28. Kumari K, Murthy PSR, Sahib MK: Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats. Experientia 47:252-254, 1991
29. Kumari K, Umar S, Bansal U, Sahib MK: Inhibition of diabetes-associated complications by nucleophilic compounds. Diabetes 40:1079-1084, 1991
30. Williamson JR, Chang K, Ido Y, Ostrow E, Allison W, Harlow J, Tilton RG: Aminoguanidine prevents diabetes (streptozotocin) induced increases in vascular albumin permeation in rat sciatic nerve. Diabete & Metab 16:369-370, 1990
31. Corbett J, Tilton R, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992
32. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946-950, 1992
33. Tilton R, Chang K, Hasan K, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
34. Bucala R, Tracey K, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438, 1991
35. Cunnane SC, Manku MS, Horrobin DF: Abnormal essential fatty acid composition of tissue lipids in genetically diabetic mice is partially corrected by dietary linoleic and gamma-linolenic acids. Br J Nutr 53:449-458, 1985
36. Mercuri O, Peluffo RO, Brenner RR: Depression of microsomal desaturation of linoleic to gamma-linolenic acid in the alloxan-diabetic rat. Biochim Biophys Acta 116:409-411, 1966
37. Keen H, Payan J, Allawi J, Walker J, Gamma-Linolenic Acid Multicenter Trial Group: Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 16:8-15, 1993
38. Jamal GA, Carmichael H: The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabetic Med 7:319-323, 1990
39. Ido Y, McHowat J, Chang KC, Arrigoni-Martelli E, Orfalian Z, Kilo C, Corr PB, Williamson JR: Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-L-carnitine. Diabetes 43:1469-1477, 1994
40. Morabito E, Serafini S, Corsico N, Martelli EA: Acetyl-L-carnitine effect on nerve conduction velocity in streptozotocin-diabetic rats. Arzneimforsch 43:343-346, 1993
41. Malone JI, Lowitt S, Corsico N, Orfalian Z: Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine. Int J Clinic Pharmacol Res 12:237-241, 1992
42. Ido Y, Rattarasarn M, Allison W, Orfalian Z, Arrigoni-Martelli E: Effects of acetyl-L-carnitine (AC) on functional and metabolic abnormalities in diabetic peripheral nerve (Abstract). Diabetes 42 (Suppl. 1):101A, 1993
43. Connolly AM, Pestronk A, Trotter JL, Feldman EL, Cornblath DR, Olney RK: High-titer selective serum anti-beta-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 43:557-562, 1993
44. Cullum NA, Coleman JW, Casson IF, McLean WG: Antibodies to tubulin and microtubule-associated proteins. A study in diabetes mellitus, systemic lupus erythematosus, and rheumatoid arthritis. Mol Chem Neuropathol 15:159-172, 1991
45. Sundkvist G, Lind P, Bergstrom B, Lilja B, Rabinowe SL: Autonomic nerve antibodies and autonomic nerve function in type I and type II diabetic patients. J Intern Med 229:505-510, 1991
46. Triban C, Guidolin D, Fabris M, Marini P, Schiavinato A, Dona M, Bortolami MC, Di Giamberardino L, Fiori MG: Ganglioside treatment and improved axonal regeneration capacity in experimental diabetic neuropathy. Diabetes 38:1012-1022, 1989
47. Crepaldi G, Fedele D, Tiengo A, Battistin L, Negrin P, Pozza G, Canal N, Comi GC, Lenti G, Pagano G: Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. Acta Diabetol Lat 20:265-276, 1983
48. Graf J, Halter JB, Pfeifer MA, Halar E, Brozovich F, Porte D Jr: Glycemic control and nerve conduction abnormalities in non-insulin-dependent diabetic subjects. Ann Int Med 94:307-311, 1981
49. Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS: Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 322:1078-1079, 1990
50. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412, 1989
51. Hruska RE, Chertack MM, Kravis D: Elevation of nerve growth factor receptor-truncated in the urine of patients with diabetic neuropathy. Ann NY Acad Sci 679:349-351, 1993